Compare Supplements

Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.

Any time

Subcutaneous prefilled pen/syringe (alirocumab)

5–20 mg once daily (up to 40 mg in selected high-risk patients), titrated to LDL/ApoB targets — under a clinician. A prescription drug; not a self-directed supplement regimen.

Any time

Oral tablet (rosuvastatin 5–20 mg)

• Known serious hypersensitivity to alirocumab or excipients
• Pregnancy (limited data; lipid lowering generally deferred in pregnancy)

• Statins
• Other lipid-lowering agents (ezetimibe)

• Active liver disease or unexplained persistent transaminase elevations
• Pregnancy and breastfeeding
• Known hypersensitivity to rosuvastatin

• Cyclosporine
• Gemfibrozil
• Certain antivirals / protease inhibitors